Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | |||
| Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | |||
| Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | |||
| VesiFlow | Solifenacin succinate / tamsulosin hydrochloride | Benign prostatic hyperplasia | Withdrawn | |||
| Ibrance | Palbociclib | Withdrawn | ||||
| N/A | Nab-paclitaxel | Solid tumours | Active | |||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| N/A | everolimus | Tuberous Sclerosis Complex (TSC) | Active | |||
| N/A | mepolizumab | Eosinophilic Granulomatosis with Polyangiitis | Active | |||
| N/A | Nab-paclitaxel | Gastrointestinal cancer | Active |
Last Updated : May 12, 2024